NABILONE

Azilect® (Teva) is a monoamine oxidase type B inhibitor.

DOSING INFORMATION:
The recommended oral dose as adjunctive therapy is an initial dose of 0.5 milligrams (mg) once daily and may be increased to 1 mg once daily. The dose for monotherapy is 1 mg once daily.

PHARMACOKINETICS:
Rasagiline is rapidly absorbed with an absolute bioavailability of approximately 36%. Food does not affect absorption. Protein binding is 88% to 94%. It is completely metabolized in the liver by the cytochrome P450 isoenzymes, primarily by CYP1A2. Cmax and AUC are increased in the presence of hepatic insufficiency. The majority is eliminated in the urine. A minor amount is eliminated in the feces. The half-life is 3 hours.

CAUTIONS:
Common adverse events are orthostatic hypotension, ataxia, somnolence, dyskinesia, headache, depression, weight loss, dry mouth, vomiting, constipation, nausea, dyspepsia, rash, arthralgia, falls, and flu syndrome.

CLINICAL APPLICATIONS:
Rasagiline is indicated for the treatment of the signs and symptoms of idiopathic Parkinson’s disease as initial monotherapy and as adjunct therapy to levodopa.

The information above is for use only by healthcare professionals in conjunction with clinical data and their professional judgment.